To determine whether prostate multi parametric MRI (mpMRI) and genomic biomarkers might help further defining patients with favorable intermediate risk patients (FIR) prostate cancer which could safely considered suitable for active surveillance (AS).
Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests
Falagario, Ugo G;Cormio, Luigi;Carrieri, Giuseppe;
2019-01-01
Abstract
To determine whether prostate multi parametric MRI (mpMRI) and genomic biomarkers might help further defining patients with favorable intermediate risk patients (FIR) prostate cancer which could safely considered suitable for active surveillance (AS).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Defining Prostate Cancer at Favorable Intermediate Risk_The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
161.4 kB
Formato
Adobe PDF
|
161.4 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
